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REVIEW
The choroid plexus as a site of damage 
in hemorrhagic and ischemic stroke and its role 
in responding to injury
Jianming Xiang1, Lisa J. Routhe2, D. Andrew Wilkinson1, Ya Hua1, Torben Moos2, Guohua Xi1 
and Richard F. Keep1,3*
Abstract 
While the impact of hemorrhagic and ischemic strokes on the blood–brain barrier has been extensively studied, the 
impact of these types of stroke on the choroid plexus, site of the blood-CSF barrier, has received much less atten-
tion. The purpose of this review is to examine evidence of choroid plexus injury in clinical and preclinical studies 
of intraventricular hemorrhage, subarachnoid hemorrhage, intracerebral hemorrhage and ischemic stroke. It then 
discusses evidence that the choroid plexuses are important in the response to brain injury, with potential roles in 
limiting damage. The overall aim of the review is to highlight deficiencies in our knowledge on the impact of hemor-
rhagic and ischemic strokes on the choroid plexus, particularly with reference to intraventricular hemorrhage, and to 
suggest that a greater understanding of the response of the choroid plexus to stroke may open new avenues for brain 
protection.
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Background
The choroid plexuses (CPs) are present in the lateral, 
third and fourth ventricles of the brain (LVCP, 3rd CP, 4th 
CP). Each CP is comprised of epithelial cells surrounding 
a richly vascularized core [1]. Compared to the cerebral 
capillaries that form the blood–brain barrier (BBB), CP 
capillaries are leakier with the endothelial cells having 
fenestrations, reflecting the role of the CPs in CSF secre-
tion [2–6]. The CPs are the site of the blood-CSF barrier, 
with the CP epithelial cells being linked by tight junctions 
that limit paracellular diffusion [1, 7].
Many neurological conditions result in BBB dysfunc-
tion, including ischemic and hemorrhagic strokes [8–
11]. That dysfunction participates in brain injury by, for 
example, causing vasogenic brain edema, allowing the 
entry of potentially neurotoxic compounds from blood 
to brain, and promoting leukocyte infiltration and neu-
roinflammation. In contrast to the wealth of studies on 
BBB injury, much less is known about whether CP injury 
occurs after stroke [12, 13]. One purpose of the present 
review is to discuss what is currently known about such 
injury. It addresses hemorrhagic and ischemic stroke, 
with a particular focus on the former including intraven-
tricular hemorrhage (IVH), subarachnoid hemorrhage 
(SAH) and intracerebral hemorrhage (ICH).
Another purpose is to review a body of evidence that 
the CPs respond to injury (that may be distant from the 
CP) by releasing factors that protect the brain [14–16]. 
This has led to experimental studies with CP transplanta-
tion for a variety of conditions [17–19]. That section also 
addresses a related topic, namely the role of the CP in 
leukocyte entry into the brain after injury. Results on the 
protective effects of the CP in brain injury/disease may 
help to inform studies on the role of cerebral endothelial 
cells.
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Choroid plexus as a site of injury
This section discusses evidence of CP injury in different 
forms of stroke in humans and animals. In human stud-
ies, it discusses morphological (post-mortem), imaging 
and permeability data to assess injury. One advantage of 
studies on the CP compared to the BBB is that the CSF 
(unlike the brain) can be sampled in patients, although 
it should be noted that CSF composition can reflect 
changes at both the blood-CSF and blood–brain barriers. 
In animal studies, the CP itself, as well as the CSF, can be 
sampled. Inflammatory changes will be discussed in the 
next section (CP as a responder to injury). Additionally, 
this section examines whether hemorrhage (particularly 
bleeding within the ventricles) can cause CP injury. It 
does not discuss the CP being the site of initial bleeding, 
although some evidence indicates CP hemorrhage is a 
major cause of IVH in babies born at full term [20] and 
can occur at other ages [21, 22].
Intraventricular hemorrhage
IVH commonly occurs in premature infants as a result of 
germinal matrix hemorrhage. It is a major cause of cere-
bral palsy in such infants and is often associated with later 
development of hydrocephalus [23]. In adults, intraven-
tricular extension of bleeding occurs in ~50% of patients 
with ICH and ~45% of patients with SAH [24, 25]. Such 
ventricular extension is a risk factor for poor outcome 
after both ICH and SAH [25–27]. ICH is known to cause 
perihematomal tissue damage [28] and BBB dysfunction 
[10]. Clot-derived factors, including hemoglobin, iron 
and thrombin, play a major role in ICH-induced injury 
[28]. Despite this evidence in ICH and the proximity of 
intraventricular blood to the CPs, we did not find clinical 
studies examining the effects of IVH on the CP epithe-
lial morphology in the literature. Clinically, IVH results 
in changes in CSF protein concentrations (e.g. [29–33]). 
While changes in blood-CSF barrier function are one 
parameter that can affect those concentrations, assessing 
barrier function from such data is very difficult, particu-
larly in the setting of IVH. Thus, for example, total CSF 
protein is elevated after IVH [29], but this may reflect 
protein originating from the initial hemorrhage, protein 
influx at the BBB as well as the blood-CSF barrier and 
production from brain parenchyma. Examining the CSF/
plasma ratio of specific proteins, such as albumin [30, 
32], helps address the latter point, but albumin will still 
enter CSF from the initial IVH as well as any potential 
BBB disruption.
In animals, Simard et al. [34] examined a rat IVH model 
at 2 days and found induction of inflammatory signaling 
(nuclear factor κB activation) within the CP along with 
a significant intracellular uptake of IgG. Furthermore, 
Gram et al. [35] found a marked inflammatory response 
in a rabbit preterm model of IVH at 1 and 3  days. This 
was accompanied by CP cell death, caspase activation 
and pronounced ultrastructural changes. Similar induc-
tions in inflammatory mediators and cell death were 
obtained in vitro when CP epithelial cells were exposed 
to met-hemoglobin, heme or CSF from preterm babies 
with IVH [35]. The hemoglobin scavenger, haptoglobin, 
prevented the adverse effects of IVH in vivo and hemo-
globin or IVH CSF in vitro [35].
In contrast, Pang et al. [36] found only subtle changes 
in CP morphology at 3 months in a dog IVH model. In 
comparison, the ependymal lining of the lateral ventri-
cles was destroyed or interrupted in many areas. Inter-
estingly, they also examined the effects of urokinase in 
their model to lyse the IVH and found that this protected 
the ependyma but also resulted in CP atrophy in some 
animals for unknown reasons. While it is possible that 
there may be species differences in the effects of IVH on 
the CP, a more likely reason for the differences between 
the studies are the time points examined. As described 
below, in SAH and ischemia there is evidence of acute 
injury followed by a recovery in CP structure, although 
the latter may be accompanied by a reduction in CP size. 
Acute studies (1–3  days) in larger species and chronic 
studies in rodents would be informative (Fig. 1).
As opposed to the paucity of data on CP injury in 
human IVH or animal models, there is considerable data 
on damage to the ependymal cells that line the cerebral 
ventricles. Thus, Fukumizu et  al. [37, 38] found marked 
ependymal damage and loss in human neonatal IVH. 
Mayfrank et al. [39] used a pig IVH model with and with-
out tissue plasminogen activator-induced fibrinolysis 
and, similar to Pang et al. [36] in dog, they found marked 
IVH-induced ependymal damage at 1 and 7  weeks and 
that was reduced by fibrinolysis. In rat, Simard et al. [34] 
found that ependymal cells took up IgG at 48 h post IVH 
and Gao et al. [40] found ependymal damage 1 day after 
intracerebroventricular (ICV) injection of Fe3+, a degra-
dation product of hemoglobin. These results indicate that 
there can be acute and chronic ependymal damage after 
IVH. In the CP after ischemic injury, there is evidence 
of tissue repair with time (see below). Why this does not 
happen in the ependyma is uncertain but it might relate 
to the ability of the CP to shrink in size when shedding 
dead cells. Because of the physical contact between the 
ependyma and underlying brain, such shrinkage is not 
possible for the ependyma.
Subarachnoid hemorrhage
SAH is often associated with extension of blood into the 
ventricular system (30–50%; [25, 27]). IVH is a risk fac-
tor for poor prognosis in SAH and for the development 
of hydrocephalus and vasospasm [25, 27, 41]. Rosen 
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et  al. [25] found that hydrocephalus developed in 62% 
of SAH patients with IVH compared to 26% of patients 
without IVH. Post-hemorrhagic hydrocephalus is gener-
ally assumed to result from a block in the CSF flow path-
ways or fibrosis at CSF outflow sites [42, 43]. Whether 
SAH (with or without associated IVH) causes CP injury 
has not to our knowledge been examined in patients. 
Given the preclinical data indicating that SAH causes CP 
damage in animals, this gap in knowledge needs to be 
corrected.
Several studies using cisterna magna blood injection in 
rabbits have reported effects on the CP (Fig. 1). Liszczak 
et al. [44] reported CP changes including electron-dense 
cytoplasmic inclusions and expansion of the lateral and 
subcellular spaces. Yilmaz et al. [45] examined both cho-
roidal artery vasospasm and CP injury (using an injury 
scoring system) at 20 days and found evidence of a cor-
relation between choroidal artery constriction and CP 
damage after SAH. In another study, the presence of 
water filled spaces within the CP was examined at 2 and 
14 days after SAH [46]. There was a marked increase in 
the numbers of such spaces, particularly at 2 days and the 
authors hypothesized that these changes may be related 
to altered CSF secretion. Furthermore, changes in CP 
morphology, with reduced epithelial cell and microvil-
lus height, and many TUNEL-positive cells have been 
reported 10 days after SAH (24% of cells in animals sur-
viving SAH and 42% in animals that died) [47].
As in humans, animal models of SAH can also cause 
hydrocephalus. Thus, using a endovascular perforation 
model of SAH (perforation at the internal carotid artery 
bifurcation), Okobu et  al. [48] found evidence of acute 
hydrocephalus in about 40% in rats. A question that has 
not been totally resolved is whether there has to be blood 
in the ventricles to induce CP injury and hydrocephalus, 
although Okobu et al. [48] found that hydrocephalus was 
always associated with blood in the ventricular system.
Intracerebral hemorrhage
Intraventricular extension of bleeding is a common find-
ing in ICH and a risk factor for poor outcome [24, 26]. 
Whether ICH without such IVH can impact CP function 
has not been examined. Even though there is no exten-
sion of blood into the ventricular system, products from 
clot degradation may move into the CSF [49].
Ischemic stroke
In humans, the blood supply to the LVCP comes from the 
anterior, lateral posterior and medial posterior choroi-
dal arteries [50]. The blood supply to the third ventricle 
CP comes from the bilateral medial posterior choroi-
dal arteries [51], while that to the fourth ventricle CP is 
from the anterior and posterior inferior cerebellar arter-
ies and the superior cerebellar artery [52]. The rich col-
lateral circulation for each of the CPs may help protect 
them from focal ischemic events. Thus, using magnetic 
resonance imaging (MRI), only three CP infarcts have 
been described in the literature. Two related to choroidal 
artery occlusion [53, 54] and one due to a basilar artery 
occlusion [55]. Brain infarcts from anterior choroid 
Intraventricular
hemorrhage
Subarachnoid 
hemorrhage
Animal HumanAnimal Human
?ACUTE -CP INJURY ?
Repair/
Atrophy?
CHRONIC -
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Fig. 1 In general, there is a surprising lack of data on the effects of intraventricular and subarachnoid hemorrhage on choroid plexus (CP) injury, 
particularly in humans. In intraventricular hemorrhage, there are studies indicating acute CP damage but this may be absent in the long-term. This 
could reflect repair mechanisms (see Fig. 2 for cerebral ischemia) and there is a need for longitudinal studies in the same model. For subarachnoid 
hemorrhage, there is evidence for both acute and chronic CP injury
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artery (AChA) occlusion have been described by multiple 
groups (e.g. [56–59]). The AChA supplies multiple tis-
sues (e.g. the internal capsule, optic tract and the cerebral 
peduncle; [58]) as well as the LVCPs. Whether changes 
in LVCP function occur and contribute to the neurologi-
cal symptoms with AChA occlusion is uncertain. Infarcts 
related to the medial posterior choroidal arteries have 
rarely been described [54, 60]  (Fig.  2). There have been 
few studies on the impact of transient global cerebral 
ischemia (e.g. cardiac arrest) on CP injury/function. 
However, in patients resuscitated after cardiac arrest, an 
increased expression of advanced glycation end-product 
receptors (RAGE) in CP epithelial cells and amyloid beta 
in both CP blood vessels and on the epithelial basement 
membrane have been reported [61, 62].
In animals, a number of studies using transient 
global ischemia models have shown CP epithelial cell 
death  (Fig.  2). Thus, Pulsinelli et  al. [63], using perma-
nent bilateral basilar artery occlusion with 30 min tran-
sient common carotid artery occlusion (4VO model) in 
rats, found ischemic necrosis in the CP at 6  h and this 
is earlier than found in hippocampus suggesting selective 
vulnerability. Also, using the rat 4VO model, LVCP atro-
phy (~35%) [64] and histological damage [65] have been 
reported. Other studies have reported widespread epi-
thelial cell death and CP edema early during reperfusion 
(0–12  h) after bilateral common carotid artery occlu-
sion (10  min) with hypotension (2VO  +  hypotension) 
[66, 67]. Furthermore, CP DNA fragmentation occurred 
after 2VO + hypotension in rats at 18–24 h [68, 69]. In 
gerbils with 5 min bilateral common carotid artery occlu-
sion with reperfusion, CP DNA fragmentation was found 
at ~1 week [70, 71].
In neonatal rats, Rothstein and Levinson [72] found 
that perinatal hypoxia/ischemia caused cell death in the 
CP and they concluded that the CP is selectively vulner-
able. Likewise, Towfighi et al. [73] found pyknotic nuclei 
within the rat CP a few hours after hypoxia/ischemia and 
this progressed to necrosis by 24  h. Interestingly, simi-
lar to the adult, those necrotic cells disappeared within 
4  days of the CP becoming atrophied. Sivakumar et  al. 
[74] examined the effects of 2 h of hypoxia alone in neo-
natal rats and found CP morphological signs of injury at 
3 and 24 h. These began to resolve at 3 days with the CPs 
having a normal appearance at 14 days. It should be noted 
that one study in neonatal mice reported no damage to 
the CP after hypoxia/ischemia injury [75]. It is interesting, 
however, that many of these studies report a recovery in 
CP structure and loss of damaged cells with time [63, 64, 
66–69, 73]. This recovery may reflect the loss of damaged 
cells, the recruitment of new cells or both. The CP atrophy 
reported by Dienel [64] and Towfighi et al. [73] suggests 
the former, but there is some evidence for cell recruitment 
(see below). In terms of blood-CSF barrier function, bar-
rier disruption was reported by Ikeda et al. [70] after bilat-
eral common carotid occlusion in the gerbil. Similarly, 
Ennis and Keep [76] reported blood-CSF barrier disrup-
tion at 6 h after 2VO + hypotension in the rat.
Global Cerebral 
Ischemia
Focal Cerebral 
Ischemia
Collaterals
Animal HumanAnimal Human
CP 
INJURY
RARE CP 
INFARCT
CP 
INJURY ?
BCSFB 
DISRUPTION
BCSFB 
DISRUPTION
Rapid Repair/
Atrophy
Repair?
Atrophy?
-
-
-
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-
Fig. 2 In animal studies, there is evidence that both transient global cerebral ischemia and focal cerebral ischemia cause choroid plexus (CP) injury 
and blood-CSF barrier (BSCFB) disruption. There is evidence that the damage after global ischemia is quickly repaired and this probably involves 
shedding of damaged cells resulting in CP atrophy. This has not been examined in focal cerebral ischemia. In humans, the effects of transient global 
cerebral ischemia (e.g. cardiac arrest) on the CP have not been examined. There are very rare reports of CP infarcts after focal cerebral ischemia in 
patients, but the occurrence of CP damage after focal cerebral ischemia is almost certainly limited by the rich collateral circulation to the CP
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There have been few studies on CP injury after focal 
ischemia [76–79]  (Fig.  2). It should be noted that the 
commonly used suture model of middle cerebral artery 
(MCA) occlusion can result in reduced blood supply to 
the LVCP [76] as the branch point for the AChA from 
the internal carotid artery is close to the bifurcation of 
the MCA [80]. In the rat, Ennis and Keep [76] found a 
38% decrease in LVCP blood flow after MCA occlusion 
and there was a 53% reduction if the animals underwent 
a tandem common carotid artery occlusion. Nagahiro 
et  al. [79] examined the effects of different durations of 
tandem MCA and internal carotid occlusion in rats. They 
found evidence of blood-CSF barrier disruption with 
MRI using gadolinium-diethylene triamine pentaacetic 
acid (Gd-DTPA) in animals with 15 and 30  min of 
ischemia with 6 h of reperfusion, whereas BBB disruption 
was only found with longer (60 min) periods of ischemia. 
They did not find evidence of CP morphological changes 
after 6  h of reperfusion by H&E staining. Li et  al. [78], 
studying 2  h transient MCA occlusion and reperfusion 
in rats, reported that CP cells became swollen (1–4 days) 
and that there was bromodeoxyuridine (BrdU) staining 
indicating cell proliferation, perhaps in compensation 
for CP cell death. No BrdU staining was observed in the 
CP in non-ischemic rats. Interestingly, the BrdU staining 
after MCA occlusion was not limited to the LVCP, but 
also occurred in the 3rd and 4th CPs indicating effects 
on proliferation distant to the ischemic parenchyma. Gil-
lardon et al. [77] found evidence of LVCP epithelial cell 
death (TUNEL staining) after 6 h but not 1.5 h of perma-
nent MCA occlusion in the rat and Ennis and Keep [76] 
found evidence of LVCP edema after MCA occlusion in 
rats with and without tandem common artery occlusion.
A number of co-morbidities increase the risk of 
ischemic stroke and result in more severe brain injury 
after stroke. These include aging, hypertension, hyper-
lipidemia and hyperglycemia and they are known to 
enhance BBB dysfunction after stroke [81]. The effects of 
such co-morbidities on CP injury after ischemic stroke 
are unknown. However, even in the absence of stroke, it 
is known that aging and Alzheimer’s disease result in CP 
dysfunction [5, 82–84].
Choroid plexus as a responder to injury
As well as being a site of injury, the CP may be involved 
in a neuroprotective response after brain injury. This 
includes CP secretion of protective factors, the CP as a 
site of neurogenesis/progenitor cell migration, the CP as 
a site of leukocyte infiltration (although this may have 
beneficial and detrimental effects) and potential changes 
in CSF production (Fig. 3). The evidence on such roles is 
limited and, therefore, this section discusses brain injury/
disease in general and not just stroke. It should be noted 
that responses can be to brain injuries that are distant 
to the CP raising the question of how those injuries are 
‘sensed’.
Growth factor/neuropeptide release
The CPs produce a wide range of peptides/proteins: e.g. 
adrenomedullin, basic fibroblast growth factor (bFGF)-2, 
insulin-like growth factor (IGF)-2, transthyretin, trans-
forming growth factor (TGF) β and vasopressin, many 
of which are secreted into the CSF [14–16]. There they 
can impact periventricular cells but they may also have 
an autocrine function since the CPs also possess an array 
of receptors: e.g. the FGFR1 and FGFR2 for fibroblast 
growth factor, IGF-1R and IGF-2R for insulin-like growth 
factor, TβRII for TGFβ, and the vasopressin receptors 
V1a, V1b and, during development, V2 [14]. There is evi-
dence of CP-induced neuroprotection via growth factor 
release in a number of injury and disease states including 
stroke (see below) and traumatic brain injury [15, 85]. It 
should be noted, however, that some peptide release by 
the CP can have adverse effects. Thus, for example, there 
is evidence that vasopressin exacerbates brain injury after 
stroke [14].
With respect to animal models of stroke, studies have 
focused on cerebral ischemia and not the CP response 
to cerebral hemorrhage. Knuckey et  al. [86] found 
that TGFβ-1, -2 and -3 mRNA expression in the CP 
increased at day 1 and 2 after transient global ischemia 
(2VO  +  hypotension), returning to normal at day 3. 
Those changes in mRNA expression were not mirrored in 
altered CP protein expression and it was suggested that 
increased mRNA levels might reflect secretion into CSF. 
Increases in CSF TGFβ-1 have been reported in ischemic 
stroke and SAH [87, 88]. In cerebral ischemia, TGFβ-1 
appears to be neuroprotective [89, 90] but it may have an 
adverse effect in IVH-induced and other forms of hydro-
cephalus [42, 91].
Hayamizu et  al. [92] used immunohistochemistry to 
examine the effects of transient global cerebral ischemia 
(2VO +  hypotension) on bFGF-2 expression in the CP 
and found that ischemia caused a marked decrease in 
cytoplasmic (but not apical or lateral membrane associ-
ated) expression from 6 h to 14 days post-ischemia. The 
loss of cytoplasmic staining was interpreted as reflecting 
CP to CSF secretion. Since ICV injection of bFGF-2 is 
protective in animal models of global ischemia [93, 94], 
this suggests that CP secretion has a protective role. Beil-
harz et  al. [95] examined the response of IGF-1 and -2 
and different IGF binding proteins (IGFBP) to hypoxia/
ischemia in 3  weeks-old rats. They found that IGFBP-6 
mRNA and protein was induced in the CP (as well as 
the ependymal and reactive glial cells) and hypothesized 
that IGFBP-6 binds particularly to IGF-2 limiting adverse 
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effects of IGF-2 after hypoxia/ischemia. Sivakumar et al. 
[74] found increased VEGF mRNA and protein levels in 
the CP at different times after 2 h of hypoxia in neonatal 
rats. VEGF expression is regulated by hypoxia-inducible 
factor α and VEGF concentrations in CSF are increased 
by conditions causing brain hypoxia [96]. Additionally, 
there are multiple papers indicating a protective effect 
of ICV administered VEGF in ischemic stroke [97–100] 
suggesting that CP production of VEGF could have pro-
tective effects in stroke. However, it should be noted that 
Liu et al. [101] recently found that ICV administration of 
an anti-VEGF receptor-2 antibody reduced early brain 
injury in a mouse SAH model.
A concern with such growth factor studies is that using 
data on CP mRNA or protein expression to imply secre-
tion into CSF could be misleading. It should be noted, 
however, that there is also in  vitro data indicating such 
secretion. For example, Borlongan et  al. [18] found that 
CP explants secrete glial-derived neurotrophic factor, 
brain-derived neurotrophic factor and nerve growth fac-
tor. Another concern is the relative importance of the CPs 
in secreting such factors into CSF after stroke compared 
to other brain areas. Data using selective inhibition of CP 
growth factor production during stroke would be very 
informative (e.g. CP specific inducible KO mice; [102]).
With respect to human stroke, Flood et al. [87] exam-
ined CSF TGFβ1 in patients who had hydrocephalus 
after SAH and found markedly increased CSF levels 
early and late after SAH. While the initial rise was prob-
ably related to platelet-derived TGFβ1, the authors 
found that late increase in CSF levels correlated with 
increased CP expression. Adrenomedullin is a vasoac-
tive peptide that is secreted by the CP and other non-
BBB areas of the brain. After SAH, there is an early (day 
3) and particularly a late (day 8) increase in CSF adre-
nomedullin that does not correlate with plasma levels. 
Higher CSF levels were correlated with an increased 
risk of delayed ischemic neurological deficits, occur-
rence of hyponatremia and reduced appetite [103, 104]. 
Whether the elevated CSF adrenomedullin levels are 
due to increased CP secretion has not been directly 
examined.
Apart from secreting proteins directly into CSF, 
recent evidence indicates that CP epithelial cells also 
secrete exosomes into the CSF [105–107]. These con-
tain proteins, microRNAs and other components and 
form another type of communications between CP and 
the brain parenchyma [105–107]. The role of exosomes 
in the protective effects of the CP in brain injury is still 
unclear.
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CHOROID 
PLEXUS
Growth 
Factors
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Fig. 3 As well as being a potential site of injury after stroke, the choroid plexus (CP) also responds to stroke in multiple ways that may modify brain 
injury. It should be noted that the potential protective CP responses may be elicited by injury distant from the CP, indicating an unknown signaling 
mechanism. While most of the CP responses are thought to be protective, the effects of leukocyte diapedesis and changes in CSF production (if 
any) are uncertain. Elucidation of protective mechanisms involving the CP led to studies where CPs or CP epithelial cell transplants were used in 
animals with ischemic stroke with evidence of neuroprotection
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Choroid plexus enzymes and transporters
As well as secreting factors that may influence brain 
damage, the CPs also express many enzymes and trans-
porters that may be important in the response to injury. 
Thus, unlike the CSF, the CP has high fibrinolytic activ-
ity [108, 109] and this may play a role in intraventricular 
hematoma resolution. In addition, considering the role 
that iron, as a degradation product of hemoglobin, has 
in brain injury after cerebral hemorrhage [28, 110, 111], 
it is noteworthy that the CP expresses a very wide array 
of iron-handling proteins including transporters: e.g. 
divalent metal transporter-1, ferroportin, transferrin 
and transferrin receptor-1 and -2, the iron storage pro-
tein ferritin, the heme metabolizing enzyme heme oxy-
genase-1, and proteins that change the oxidative sate of 
iron (ceruloplasmin and hephaestin) [112, 113]. The role 
of the CP in handling hemoglobin and iron after IVH 
merits further investigation. In relation to Alzheimer’s 
disease, the CP plays a role in regulating amyloid-β deg-
radation and the levels of amyloid-β in the brain were 
reduced in a mouse model of Alzheimer’s disease by CP 
implants [17].
Choroid plexus transplantation
Because of the evidence that the CP can protect the brain 
from injury, there have been a number of studies exam-
ining the effects of CP transplants on different types of 
brain injury. Borlongan et  al. found that transplanting 
rat [114] or pig [18] choroid plexus into the CNS pro-
tected against cerebral ischemia in rats. Matsumoto et al. 
[115] also showed similar protection with cultured cho-
roid plexus epithelial cells in rat MCA occlusion. Out-
side cerebral ischemia, Bolos et  al. [17] found that CP 
epithelial cell transplants reduced amyloid-β deposits, 
tau hyperphosphorylation and astrocytic reactivity in a 
mouse model of Alzheimer’s disease. They also improved 
behavioral outcomes including memory tests. Similarly, 
transplants of CP epithelial cells have enhanced axonal 
regeneration and locomotor improvement in rat spinal 
cord injury [19, 116]. Compared to approaches that focus 
on a single factor (e.g. a growth factor) to promote brain 
protection/recovery, CP epithelial cells transplants may 
have an advantage in producing multiple factors. It is also 
possible that the CP epithelial cells may have a modified 
response dependent upon the type of injury. Thus, for 
example, will CP epithelial cells exposed to an ischemic 
brain produce the same growth factor and express the 
same enzymes as those exposed to a brain with Alzhei-
mer’s disease?
Choroid plexus proliferation and progenitor cells
In the adult CP, there is only a slow turnover of epithelial 
cells in rodents and primates [117, 118]. However, there 
is in  vitro evidence that injury and growth factors (IGF 
and epidermal growth factor) can cause CP epithelial cell 
proliferation [119]. In vivo, Li et al. [78] found increased 
CP cell proliferation (BrdU positive cells) after MCA 
occlusion in the rat. The overall impact of such prolifera-
tion on CP injury in  vivo is as yet uncertain (i.e. can it 
replace the cell loss caused by stroke?) and some of the 
BrdU cells were neuronal nuclear antigen (NeuN) and 
glial fibrillary acidic protein positive leading Li et  al. to 
suggest they were neural precursor cells [78].
There has been considerable interest in the use of exog-
enous stem cells, either administered systemically or 
into the brain, to treat different neurological conditions. 
Endothelial progenitor cells administered intravenously 
can integrate into the cerebral endothelium after stroke 
and may be a source of growth factors [120]. Whether 
that is the case for the CP is unclear. Zhang et al. [121] 
found that bone marrow-derived endothelial progenitor 
cells migrated to the CP endothelium after intravenous 
injection in non-ischemic mice and Beck et al. [122] also 
found that bone marrow-derived cells given intrave-
nously migrated to the CP in ischemic (MCA occlusion) 
and non-ischemic mice. They were uncertain whether 
those cells were integrating into the CP endothelium or 
migrating through the CP. However, mesenchymal stem 
cells given ICV can integrate into the CP epithelium [123, 
124].
Leukocyte migration at the choroid plexus
In stroke, neuroinflammation may have both detrimen-
tal and beneficial effects. Thus, an early influx of leu-
kocytes (particularly neutrophils) into the brain from 
the blood may exacerbate ischemic and hemorrhagic 
brain injury [125, 126], but a later inflammation may be 
beneficial in brain repair [127–129]. In the case of cer-
ebral hemorrhage, infiltrating macrophages/resident 
microglia have an important role in hematoma resolu-
tion via phagocytosis [130, 131]. Infiltrating leukocytes 
may enter the brain across the BBB or the blood-CSF 
barrier after a stroke. While there is a wealth of knowl-
edge about leukocyte entry at the BBB in stroke, stud-
ies on the role of the CP are very limited. Kowarik et al. 
[132] compared CSF levels of leukocytes in patients 
across multiple neurological conditions. For stroke (a 
mixture of ischemic and hemorrhagic), they examined 
CSF within 4  weeks of onset. Unlike some conditions 
(e.g. bacterial or viral meningitis), stroke was not asso-
ciated with high CSF leukocyte counts nor did it alter 
the distribution of leukocyte subsets. The majority of 
CSF leukocytes after stroke were CD4+ T cells (71%) 
and CD8+ T cells (17%). A fuller time course of such 
changes in CSF, particularly soon after stroke, would be 
informative.
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The CP is thought to be involved in immune surveil-
lance by trafficking T-lymphocytes [133, 134]. In a 
model of hypoxia/ischemia with systemic inflammation 
(lipopolysaccharide; to mimic intrauterine infection) in 
rats, Yang et al. [135] found an early (4 h) infiltration of 
T-lymphocytes (CD43+) into the CP. This was blocked by 
fingolimod (FTY720; a sphingosine-1-phosphate recep-
tor modulator) treatment which also markedly reduced 
the brain injury in lipopolysaccharide-enhanced hypoxia/
ischemia injury. In other neurological conditions, such 
as multiple sclerosis, traumatic brain injury, spinal cord 
injury and meningitis, as well as peripheral inflammation, 
there has been interest in the role of the CP in leuko-
cyte entry into CSF and brain [3, 136, 137]. For example, 
Szmydynger-Chodobska et  al. [138, 139] found that the 
CP is a site of neutrophil and monocyte entry into the 
brain after traumatic brain injury (controlled cortical 
impact). It is interesting that in those studies the CPs are 
distant from the site of initial injury raising the question 
as to what signaling mechanisms trigger the diapedesis of 
leukocytes at the CP.
CSF production
Alterations in CSF production could impact brain injury. 
Increases could aid in the clearance of neurotoxic factors 
from the brain (CSF sink effect) but might also exacerbate 
hydrocephalus. With regards to the latter, choroid plexus 
hyperplasia and choroid plexus papillomas are associ-
ated with CSF hypersecretion and hydrocephalus [140]. 
Decreases in CSF production might serve to decrease the 
incidence of hydrocephalus and reduce intracranial pres-
sure, and CP cauterization has been used as a treatment 
for hydrocephalus [141, 142]. After stroke, there is a lack 
of data on whether CSF production is changed. However, 
Holloway and Cassin [143] did report a 33% decline in 
CSF production with hypoxia in neonatal dogs.
The water channel, aquaporin 1 (Aqp1) is highly 
expressed in the CP epithelium and Aqp1 knockout 
mice have reduced CSF secretion [144]. There has, there-
fore, been an interest in examining the effects of stroke 
on Aqp1 expression. In the 4VO model of transient 
global cerebral ischemia, Akdemir et al. [65] reported an 
increase AQP1 protein expression in the CP epithelium 
between 24 and 48  h of reperfusion. Similarly, Sveins-
dottir et al. [145] found an increase in CP Aqp1 protein 
expression in a preterm rabbit IVH model. However, at 
the mRNA level, there was a decrease in expression, an 
effect replicated in  vitro by exposing cultured CP epi-
thelial cells to the CSF of preterm infants with IVH or 
hemin. The reason for the different protein and mRNA 
responses are uncertain. Interestingly, Sveinsdottir et al. 
[145] also examined the expression of another aquaporin, 
Aqp5. They found a marked increase in both protein 
and mRNA expression in the preterm rabbit IVH model 
for that aquaporin and they also found increased Aqp5 
mRNA after exposure of CP epithelial cells to hemin 
in vitro. This merits further investigation.
Injury sensing by the choroid plexus
In the earlier descriptions of stroke-induced CP injury, 
this review has focused on types of injury that directly 
impact the CP, including reductions in CP blood flow 
or blood in the ventricular system adjacent to the CPs. 
However, there is evidence that events distant from 
the CPs may trigger protective responses in the CP. For 
example, traumatic brain injury that does not directly 
impact the CP results in growth factor production [15, 
85], alters CP protein expression (e.g. [146]), and infiltra-
tion of leukocytes across the CP [138], and Li et al. [78] 
found increased cell proliferation in CPs distant to the 
parenchymal damage induced by a MCA occlusion. How 
does the CP sense that distant injury and what pathways 
in the CP are triggered to elicit the protective response? 
As noted above, the CP expresses a wide range of pep-
tide/protein receptors [14] and these may be involved, 
but these are as yet largely unaddressed questions.
Choroid plexus and cerebral endothelial responses 
to stroke
Our knowledge of the effects of stroke on cerebral 
endothelial cells, the site of the BBB, is much greater 
than at the CP epithelium. There are also differences in 
the types of experiment that can be performed in relation 
to each tissue. For example, with the cerebral endothe-
lium, two-photon microscopy using fluorescently-tagged 
permeability markers and endothelial proteins (e.g. cells 
expressing GFP-tagged claudin-5) can be used to study 
stroke-induced BBB disruption in real time [147]. Such 
techniques can not currently be used to study the deeply-
situated CPs. However, CP studies have an advantage 
in that CSF can be sampled (in animals and humans) 
in contrast to the cerebral endothelium studies where 
adjacent brain interstitial fluid is inaccessible. Thus, for 
example, the sampling of exosomes released from cere-
bral endothelial cells is currently limited to cultured cells 
[148]. While acknowledging that other sites (e.g. epend-
yma), as well as the CP, may contribute to CSF exosomes, 
analysis of such exosomes has given insight into exo-
some cargo in animals and humans in vivo (e.g. proteins, 
mRNAs and microRNAs [149–151]) as well as the impact 
of disease on exosomes [152].
Access to CSF has aided examination of the potential 
roles of the CP in protecting the brain from injury/dis-
ease. The results of such CP studies may aid in formulat-
ing brain endothelial studies. For example, to what extent 
will brain endothelial cells fulfil similar protective roles to 
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the CP? While there has been considerable interest in the 
production of growth factors by neural and endothelial 
progenitor cells (endogenous and exogenous) after injury 
[153, 154], the role of the normal cerebral endothelium 
has received less attention.
Conclusions
There have been surprisingly few studies examining the 
degree to which hemorrhagic stroke causes CP injury. 
This is particularly noticeable in the setting of IVH, 
where the CP is in close proximity to the hemorrhage. 
In ICH, there is considerable evidence that clot derived 
factors (e.g. hemoglobin and iron) cause perihematomal 
injury [28] and are a therapeutic target (intracerebral 
hemorrhage deferoxamine trial; iDEF—NCT02175225). 
Further clinical and preclinical studies on the extent to 
which IVH and SAH cause CP injury are needed as they 
may identify a therapeutic target.
Because of its rich collateral circulation, focal cerebral 
ischemia probably rarely causes CP infarction. However, 
there is evidence suggesting that the CP is selectively 
vulnerable to ischemia. Further studies on the impact of 
transient global ischemia (e.g. cardiac arrest) on CP injury 
in patients are warranted. The finding that the CPs can 
produce factors that can protect the brain from injury and 
disease raises many opportunities. The factors involved 
are probably numerous, making the effects difficult to 
reproduce pharmacologically (especially within the brain). 
Hence, there has been an interest in using CP transplants. 
However, there is a question as to what can trigger the 
release of protective factors from the CP? Determining 
the signaling pathway(s) may be a promising therapeu-
tic avenue. It should also be noted that a role of the CP 
in neuroprotection after IVH or SAH has not really been 
examined and this may be an important area of research.
Authors’ contributions
All the authors contributed to the writing and editing of this manuscript. All 
authors read and approved the final manuscript.
Author details
1 Department of Neurosurgery, University of Michigan, R5018 BSRB, 109 Zina 
Pitcher Place, Ann Arbor, MI 48109-2200, USA. 2 Department of Health Sci-
ence and Technology, Aalborg University, Aalborg, Denmark. 3 Department 
of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, USA. 
Acknowledgements
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All authors have read the final version of the manuscript and consented to 
publication.
Funding
This work was supported by the National Institutes of Health Grants NS073595, 
NS079157, NS090925, NS091545, NS093399, NS096917 and NS007222. The 
content is solely the responsibility of the authors and does not necessarily 
represent the official views of the NIH. Lisa Juul Routhe is recipient of a Ph.D-
stipend obtained from the Lundbeck foundation (Grant No: R191-2015-1360).
Received: 26 January 2017   Accepted: 8 March 2017
References
 1. Redzic ZB, Segal MB. The structure of the choroid plexus and the 
physiology of the choroid plexus epithelium. Adv Drug Deliv Rev. 
2004;56(12):1695–716.
 2. Damkier HH, Brown PD, Praetorius J. Cerebrospinal fluid secretion by 
the choroid plexus. Physiol Rev. 2013;93(4):1847–92.
 3. Demeestere D, Libert C, Vandenbroucke RE. Clinical implications of 
leukocyte infiltration at the choroid plexus in (neuro)inflammatory 
disorders. Drug Discov Today. 2015;20(8):928–41.
 4. Hladky SB, Barrand MA. Mechanisms of fluid movement into, through 
and out of the brain: evaluation of the evidence. Fluids Barriers CNS. 
2014;11(1):26.
 5. Marques F, Sousa JC, Brito MA, Pahnke J, Santos C, Correia-Neves M, 
Palha JA. The choroid plexus in health and in disease: dialogues into 
and out of the brain. Neurobiol Dis. 2016. doi:10.1016/j.nbd.2016.08.011.
 6. Spector R, Johanson CE. Sustained choroid plexus function in 
human elderly and Alzheimer’s disease patients. Fluids Barriers CNS. 
2013;10(1):28.
 7. Tietz S, Engelhardt B. Brain barriers: crosstalk between complex tight 
junctions and adherens junctions. J Cell Biol. 2015;209(4):493–506.
 8. Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, Sharp FR. Hemor-
rhagic transformation after ischemic stroke in animals and humans. J 
Cereb Blood Flow Metab. 2014;34(2):185–99.
 9. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for 
blood-brain barrier disruption in ischemic stroke: critical role of matrix 
metalloproteinases and tissue-type plasminogen activator. Neurobiol 
Dis. 2010;38(3):376–85.
 10. Keep RF, Zhou N, Xiang J, Andjelkovic AV, Hua Y, Xi G. Vascular disrup-
tion and blood-brain barrier dysfunction in intracerebral hemorrhage. 
Fluids Barriers CNS. 2014;11:18.
 11. Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and 
chronic cerebrovascular disease. Stroke. 2011;42(11):3323–8.
 12. Ennis SR, Keep RF. Forebrain ischemia and the blood-cerebrospinal fluid 
barrier. Acta Neurochir Suppl. 2006;96:276–8.
 13. Keep RF, Ennis SR, Xiang J. The blood-CSF barrier and cerebral ischemia. 
In: Zheng W, Chodobski A, editors. The blood-cerebrospinal fluid barrier. 
Boca Raton: Taylor & Francis; 2005. p. 345–60.
 14. Chodobski A, Szmydynger-Chodobska J. Choroid plexus: target 
for polypeptides and site of their synthesis. Microsc Res Tech. 
2001;52(1):65–82.
 15. Johanson C, Stopa E, Baird A, Sharma H. Traumatic brain injury and 
recovery mechanisms: peptide modulation of periventricular neu-
rogenic regions by the choroid plexus-CSF nexus. J Neural Transm. 
2011;118(1):115–33.
 16. Redzic ZB, Preston JE, Duncan JA, Chodobski A, Szmydynger-Chodob-
ska J. The choroid plexus-cerebrospinal fluid system: from development 
to aging. Curr Top Dev Biol. 2005;71:1–52.
 17. Bolos M, Antequera D, Aldudo J, Kristen H, Bullido MJ, Carro E. Choroid 
plexus implants rescue Alzheimer’s disease-like pathologies by modu-
lating amyloid-beta degradation. Cell Mol Life Sci. 2014;71(15):2947–55.
 18. Borlongan CV, Skinner SJ, Geaney M, Vasconcellos AV, Elliott RB, Emerich 
DF. Intracerebral transplantation of porcine choroid plexus provides 
structural and functional neuroprotection in a rodent model of stroke. 
Stroke. 2004;35(9):2206–10.
 19. Ide C, Nakano N, Kanekiyo K. Cell transplantation for the treatment 
of spinal cord injury—bone marrow stromal cells and choroid plexus 
epithelial cells. Neural Regen Res. 2016;11(9):1385–8.
 20. Lacey DJ, Terplan K. Intraventricular hemorrhage in full-term neonates. 
Dev Med Child Neurol. 1982;24(3):332–7.
 21. Miyasaka Y, Yada K, Ohwada T, Morii S, Kitahara T, Kurata A, Tanaka 
R. Choroid plexus arteriovenous malformations. Neurol Med Chir. 
1992;32(4):201–6.
Page 10 of 13Xiang et al. Fluids Barriers CNS  (2017) 14:8 
 22. Reeder JD, Kaude JV, Setzer ES. Choroid plexus hemorrhage in prema-
ture neonates: recognition by sonography. AJNR Am J Neuroradiol. 
1982;3(6):619–22.
 23. Ballabh P. Intraventricular hemorrhage in premature infants: mecha-
nism of disease. Pediatr Res. 2010;67(1):1–8.
 24. Bhattathiri PS, Gregson B, Prasad KS, Mendelow AD, Investigators S. 
Intraventricular hemorrhage and hydrocephalus after spontaneous 
intracerebral hemorrhage: results from the STICH trial. Acta Neurochir 
Suppl. 2006;96:65–8.
 25. Rosen DS, Macdonald RL, Huo D, Goldenberg FD, Novakovic RL, Frank 
JI, Rosengart AJ. Intraventricular hemorrhage from ruptured aneurysm: 
clinical characteristics, complications, and outcomes in a large, pro-
spective, multicenter study population. J Neurosurg. 2007;107(2):261–5.
 26. Hanley DF. Intraventricular hemorrhage: severity factor and treat-
ment target in spontaneous intracerebral hemorrhage. Stroke. 
2009;40(4):1533–8.
 27. Jabbarli R, Reinhard M, Roelz R, Shah M, Niesen WD, Kaier K, Taschner 
C, Weyerbrock A, Velthoven VV. The predictors and clinical impact of 
intraventricular hemorrhage in patients with aneurysmal subarachnoid 
hemorrhage. Int J Stroke. 2016;11(1):68–76.
 28. Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury 
and therapeutic targets. Lancet Neurol. 2012;11(8):720–31.
 29. Hallevi H, Walker KC, Kasam M, Bornstein N, Grotta JC, Savitz SI. Inflam-
matory response to intraventricular hemorrhage: time course, magni-
tude and effect of t-PA. J Neurol Sci. 2012;315(1–2):93–5.
 30. Kaestner S, Dimitriou I. TGF beta1 and TGF beta2 and their role in post-
hemorrhagic hydrocephalus following SAH and IVH. J Neurol Surg Part 
A Cent Eur Neurosurg. 2013;74(5):279–84.
 31. Kramer AH, Jenne CN, Zygun DA, Roberts DJ, Hill MD, Holodinsky 
JK, Todd S, Kubes P, Wong JH. Intraventricular fibrinolysis with tissue 
plasminogen activator is associated with transient cerebrospinal fluid 
inflammation: a randomized controlled trial. J Cereb Blood Flow Metab. 
2015;35(8):1241–8.
 32. Milman N, Graudal NA, Olsen TS, Wandall JH, Pedersen NS. Cerebrospi-
nal fluid ferritin in patients with meningitis and cerebral infarction or 
bleeding. Dan Med Bull. 1993;40(4):490–2.
 33. Morales DM, Silver SA, Morgan CD, Mercer D, Inder TE, Holtzman DM, 
Wallendorf MJ, Rao R, McAllister JP, Limbrick DD Jr. Lumbar cerebrospi-
nal fluid biomarkers of posthemorrhagic hydrocephalus of prematurity: 
amyloid precursor protein, soluble amyloid precursor protein alpha, 
and L1 cell adhesion molecule. Neurosurgery. 2017;80(1):82–90.
 34. Simard PF, Tosun C, Melnichenko L, Ivanova S, Gerzanich V, Simard 
JM. Inflammation of the choroid plexus and ependymal layer of the 
ventricle following intraventricular hemorrhage. Transl Stroke Res. 
2011;2(2):227–31.
 35. Gram M, Sveinsdottir S, Cinthio M, Sveinsdottir K, Hansson SR, Morgelin 
M, Akerstrom B, Ley D. Extracellular hemoglobin—mediator of 
inflammation and cell death in the choroid plexus following preterm 
intraventricular hemorrhage. J Neuroinflammation. 2014;11:200.
 36. Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular blood clot with 
urokinase in a canine model: Part 3. Effects of intraventricular urokinase 
on clot lysis and posthemorrhagic hydrocephalus. Neurosurgery. 
1986;19(4):553–72.
 37. Fukumizu M, Takashima S, Becker LE. Neonatal posthemorrhagic hydro-
cephalus: neuropathologic and immunohistochemical studies. Pediatr 
Neurol. 1995;13(3):230–4.
 38. Fukumizu M, Takashima S, Becker LE. Glial reaction in periventricu-
lar areas of the brainstem in fetal and neonatal posthemorrhagic 
hydrocephalus and congenital hydrocephalus. Brain Develop. 
1996;18(1):40–5.
 39. Mayfrank L, Kim Y, Kissler J, Delsing P, Gilsbach JM, Schroder JM, Weis J. 
Morphological changes following experimental intraventricular haem-
orrhage and intraventricular fibrinolytic treatment with recombinant 
tissue plasminogen activator. Acta Neuropathol. 2000;100(5):561–7.
 40. Gao F, Liu F, Chen Z, Hua Y, Keep RF, Xi G. Hydrocephalus after intraven-
tricular hemorrhage: the role of thrombin. J Cereb Blood Flow Metab. 
2014;34(3):489–94.
 41. Wilson TJ, Stetler WR Jr, Davis MC, Giles DA, Khan A, Chaudhary N, Gem-
mete JJ, Xi G, Thompson BG, Pandey AS. Intraventricular hemorrhage 
is associated with early hydrocephalus, symptomatic vasospasm, and 
poor outcome in aneurysmal subarachnoid hemorrhage. J Neurol Surg. 
2015;76(2):126–32.
 42. Cherian S, Whitelaw A, Thoresen M, Love S. The pathogenesis of neona-
tal post-hemorrhagic hydrocephalus. Brain Pathol. 2004;14(3):305–11.
 43. Whitelaw A, Thoresen M, Pople I. Posthaemorrhagic ventricular dilata-
tion. Arch Dis Child Fetal Neonatal Ed. 2002;86(2):F72–4.
 44. Liszczak TM, Black PM, Tzouras A, Foley L, Zervas NT. Morphological 
changes of the basilar artery, ventricles, and choroid plexus after experi-
mental SAH. J Neurosurg. 1984;61(3):486–93.
 45. Yilmaz A, Aydin MD, Kanat A, Musluman AM, Altas S, Aydin Y, Calik M, 
Gursan N. The effect of choroidal artery vasospasm on choroid plexus 
injury in subarachnoid hemorrhage: experimental study. Turk Neuro-
surg. 2011;21(4):477–82.
 46. Kanat A, Turkmenoglu O, Aydin MD, Yolas C, Aydin N, Gursan N, 
Tumkaya L, Demir R. Toward changing of the pathophysiologic basis 
of acute hydrocephalus after subarachnoid hemorrhage: a preliminary 
experimental study. World Neurosurg. 2013;80(3–4):390–5.
 47. Kotan D, Aydin MD, Gundogdu C, Aygul R, Aydin N, Ulvi H. Parallel 
development of choroid plexus degeneration and meningeal inflam-
mation in subarachnoid hemorrhage—experimental study. Adv Clin 
Exp Med. 2014;23(5):699–704.
 48. Okubo S, Strahle J, Keep RF, Hua Y, Xi G. Subarachnoid hemorrhage-
induced hydrocephalus in rats. Stroke. 2013;44(2):547–50.
 49. Norrving B, Olsson JE. The diagnostic value of spectrophotometric 
analysis of the cerebrospinal fluid in cerebral hematomas. J Neurol Sci. 
1979;44(1):105–14.
 50. Marinkovic S, Gibo H, Milisavljevic M, Djulejic V, Jovanovic VT. Micro-
anatomy of the intrachoroidal vasculature of the lateral ventricle. 
Neurosurgery. 2005;57(1 Suppl):22–36 (discussion 22–36).
 51. Wolfram-Gabel R, Maillot C, Koritke JG, Laude M. Vascularization of 
the tela choroidea of the 3rd ventricle in man. Archives d’Anatomie, 
d’Histologie, et d’Embryologie Normales et Experimentales. 
1984;67:3–42.
 52. Sharifi M, Ciolkowski M, Krajewski P, Ciszek B. The choroid plexus of the 
fourth ventricle and its arteries. Folia Morphol. 2005;64(3):194–8.
 53. Koral K, Dowling MM, Rollins NK. Choroid plexus infarction in a child. 
Pediatr Neurol. 2007;37(6):452–3.
 54. Liebeskind DS, Hurst RW. Infarction of the choroid plexus. AJNR Am J 
Neuroradiol. 2004;25(2):289–90.
 55. Nabavizadeh SA, Tangestanipoor A, Mowla A, Hurst R, Mamourian AC. 
Infarction of the choroid plexus in basilar artery occlusion. J Neurol Sci. 
2015;358(1–2):467–8.
 56. Helgason CM. A new view of anterior choroidal artery territory infarc-
tion. J Neurol. 1988;235(7):387–91.
 57. Hupperts RM, Lodder J, Heuts-van Raak EP, Kessels F. Infarcts in the 
anterior choroidal artery territory. Anatomical distribution, clinical syn-
dromes, presumed pathogenesis and early outcome. Brain. 1994;117(Pt 
4):825–34.
 58. Pezzella FR, Vadala R. Anterior choroidal artery territory infarction. Front 
Neurol Neurosci. 2012;30:123–7.
 59. Takahashi S, Ishii K, Matsumoto K, Higano S, Ishibashi T, Suzuki M, 
Sakamoto K. The anterior choroidal artery syndrome. II. CT and/or MR in 
angiographically verified cases. Neuroradiology. 1994;36(5):340–5.
 60. Neau JP, Bogousslavsky J. The syndrome of posterior choroidal artery 
territory infarction. Ann Neurol. 1996;39(6):779–88.
 61. Maslinska D, Laure-Kamionowska M, Taraszewska A, Deregowski K, 
Maslinski S. Immunodistribution of amyloid beta protein (Abeta) 
and advanced glycation end-product receptors (RAGE) in choroid 
plexus and ependyma of resuscitated patients. Folia Neuropathol. 
2011;49(4):295–300.
 62. Wisniewski HM, Maslinska D. Beta-protein immunoreactivity in the 
human brain after cardiac arrest. Folia Neuropathol. 1996;34(2):65–71.
 63. Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal 
damage in a model of transient forebrain ischemia. Ann Neurol. 
1982;11(5):491–8.
 64. Dienel GA. Regional accumulation of calcium in postischemic rat brain. 
J Neurochem. 1984;43(4):913–25.
 65. Akdemir G, Kaymaz F, Gursoy-Ozdemir Y, Akalan N, Akdemir ES. The 
time course changes in expression of aquaporin 4 and aquaporin 1 fol-
lowing global cerebral ischemic edema in rat. Surg Neurol Int. 2016;7:4.
Page 11 of 13Xiang et al. Fluids Barriers CNS  (2017) 14:8 
 66. Johanson CE, Palm DE, Primiano MJ, McMillan PN, Chan P, Knuckey NW, 
Stopa EG. Choroid plexus recovery after transient forebrain ischemia: 
role of growth factors and other repair mechanisms. Cell Mol Neurobiol. 
2000;20(2):197–216.
 67. Palm D, Knuckey N, Guglielmo M, Watson P, Primiano M, Johanson 
C. Choroid plexus electrolytes and ultrastructure following transient 
forebrain ischemia. Am J Physiol. 1995;269(1 Pt 2):R73–9.
 68. Ferrand-Drake M. Cell death in the choroid plexus following transient 
forebrain global ischemia in the rat. Microsc Res Tech. 2001;52(1):130–6.
 69. Ferrand-Drake M, Wieloch T. The time-course of DNA fragmentation 
in the choroid plexus and the CA1 region following transient global 
ischemia in the rat brain. The effect of intra-ischemic hypothermia. 
Neuroscience. 1999;93(2):537–49.
 70. Ikeda J, Mies G, Nowak TS Jr, Joo F, Klatzo I. Evidence for increased cal-
cium influx across the choroid plexus following brief ischemia of gerbil 
brain. Neurosci Lett. 1992;142(2):257–9.
 71. Kitagawa H, Setoguchi Y, Fukuchi Y, Mitsumoto Y, Koga N, Mori T, Abe K. 
DNA fragmentation and HSP72 gene expression by adenovirus-medi-
ated gene transfer in postischemic gerbil hippocampus and ventricle. 
Metab Brain Dis. 1998;13(3):211–23.
 72. Rothstein RP, Levison SW. Damage to the choroid plexus, ependyma 
and subependyma as a consequence of perinatal hypoxia/ischemia. 
Dev Neurosci. 2002;24(5):426–36.
 73. Towfighi J, Zec N, Yager J, Housman C, Vannucci RC. Temporal 
evolution of neuropathologic changes in an immature rat model 
of cerebral hypoxia: a light microscopic study. Acta Neuropathol. 
1995;90(4):375–86.
 74. Sivakumar V, Lu J, Ling EA, Kaur C. Vascular endothelial growth factor 
and nitric oxide production in response to hypoxia in the choroid 
plexus in neonatal brain. Brain Pathol. 2008;18(1):71–85.
 75. D’Angelo B, Ek CJ, Sandberg M, Mallard C. Expression of the Nrf2-system 
at the blood-CSF barrier is modulated by neonatal inflammation and 
hypoxia-ischemia. J Inherit Metab Dis. 2013;36(3):479–90.
 76. Ennis SR, Keep RF. The effects of cerebral ischemia on the rat choroid 
plexus. J Cereb Blood Flow Metab. 2006;26(5):675–83.
 77. Gillardon F, Lenz C, Kuschinsky W, Zimmermann M. Evidence for apop-
totic cell death in the choroid plexus following focal cerebral ischemia. 
Neurosci Lett. 1996;207(2):113–6.
 78. Li Y, Chen J, Chopp M. Cell proliferation and differentiation from 
ependymal, subependymal and choroid plexus cells in response to 
stroke in rats. J Neurol Sci. 2002;193(2):137–46.
 79. Nagahiro S, Goto S, Korematsu K, Sumi M, Takahashi M, Ushio Y. Disrup-
tion of the blood-cerebrospinal fluid barrier by transient cerebral 
ischemia. Brain Res. 1994;633(1–2):305–11.
 80. He Z, Yang SH, Naritomi H, Yamawaki T, Liu Q, King MA, Day AL, Simp-
kins JW. Definition of the anterior choroidal artery territory in rats using 
intraluminal occluding technique. J Neurol Sci. 2000;182(1):16–28.
 81. Lucke-Wold BP, Logsdon AF, Turner RC, Rosen CL, Huber JD. Aging, the 
metabolic syndrome, and ischemic stroke: redefining the approach for 
studying the blood–brain barrier in a complex neurological disease. 
Adv Pharmacol. 2014;71:411–49.
 82. Serot JM, Bene MC, Faure GC. Comparative immunohistochemical 
characteristics of human choroid plexus in vascular and Alzheimer’s 
dementia. Hum Pathol. 1994;25(11):1185–90.
 83. Serot JM, Zmudka J, Jouanny P. A possible role for CSF turnover and 
choroid plexus in the pathogenesis of late onset Alzheimer’s disease. J 
Alzheimer’s Dis. 2012;30(1):17–26.
 84. Vandenbroucke RE. A hidden epithelial barrier in the brain with a 
central role in regulating brain homeostasis. Implications for aging. Ann 
Am Thorac Soc. 2016;13(Supplement_5):S407–10.
 85. Walter HJ, Berry M, Hill DJ, Cwyfan-Hughes S, Holly JM, Logan A. Distinct 
sites of insulin-like growth factor (IGF)-II expression and localization in 
lesioned rat brain: possible roles of IGF binding proteins (IGFBPs) in the 
mediation of IGF-II activity. Endocrinology. 1999;140(1):520–32.
 86. Knuckey NW, Finch P, Palm DE, Primiano MJ, Johanson CE, Flanders 
KC, Thompson NL. Differential neuronal and astrocytic expression of 
transforming growth factor beta isoforms in rat hippocampus following 
transient forebrain ischemia. Brain Res Mol Brain Res. 1996;40(1):1–14.
 87. Flood C, Akinwunmi J, Lagord C, Daniel M, Berry M, Jackowski A, 
Logan A. Transforming growth factor-beta1 in the cerebrospinal 
fluid of patients with subarachnoid hemorrhage: titers derived from 
exogenous and endogenous sources. J Cereb Blood Flow Metab. 
2001;21(2):157–62.
 88. Krupinski J, Vodovotz Y, Li C, Slowik A, Beevers D, Flanders KC, Lip G, 
Kumar P, Szczudlik A. Inducible nitric oxide production and expression 
of transforming growth factor-beta1 in serum and CSF after cerebral 
ischaemic stroke in man. Nitric Oxide. 1998;2(6):442–53.
 89. Buisson A, Lesne S, Docagne F, Ali C, Nicole O, MacKenzie ET, Vivien D. 
Transforming growth factor-beta and ischemic brain injury. Cell Mol 
Neurobiol. 2003;23(4–5):539–50.
 90. Dobolyi A, Vincze C, Pal G, Lovas G. The neuroprotective func-
tions of transforming growth factor beta proteins. Int J Mol Sci. 
2012;13(7):8219–58.
 91. Aojula A, Botfield H, McAllister JP 2nd, Gonzalez AM, Abdullah O, Logan 
A, Sinclair A. Diffusion tensor imaging with direct cytopathological vali-
dation: characterisation of decorin treatment in experimental juvenile 
communicating hydrocephalus. Fluids Barriers CNS. 2016;13(1):9.
 92. Hayamizu TF, Chan PT, Johanson CE. FGF-2 immunoreactivity in adult 
rat ependyma and choroid plexus: responses to global forebrain 
ischemia and intraventricular FGF-2. Neurol Res. 2001;23(4):353–8.
 93. Koketsu N, Berlove DJ, Moskowitz MA, Kowall NW, Caday CG, Finklestein 
SP. Pretreatment with intraventricular basic fibroblast growth factor 
decreases infarct size following focal cerebral ischemia in rats. Ann 
Neurol. 1994;35(4):451–7.
 94. Nakata N, Kato H, Kogure K. Protective effects of basic fibroblast growth 
factor against hippocampal neuronal damage following cerebral 
ischemia in the gerbil. Brain Res. 1993;605(2):354–6.
 95. Beilharz EJ, Russo VC, Butler G, Baker NL, Connor B, Sirimanne ES, Dragu-
now M, Werther GA, Gluckman PD, Williams CE, et al. Co-ordinated and 
cellular specific induction of the components of the IGF/IGFBP axis in 
the rat brain following hypoxic-ischemic injury. Brain Res Mol Brain Res. 
1998;59(2):119–34.
 96. Scheufler KM, Drevs J, van Velthoven V, Reusch P, Klisch J, Augustin HG, 
Zentner J, Marme D. Implications of vascular endothelial growth factor, 
sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cer-
ebral ischemia in man. J Cereb Blood Flow Metab. 2003;23(1):99–110.
 97. Harrigan MR, Ennis SR, Sullivan SE, Keep RF. Effects of intraventricular 
infusion of vascular endothelial growth factor on cerebral blood flow, 
edema, and infarct volume. Acta Neurochir (Wien). 2003;145(1):49–53.
 98. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial 
growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc 
Natl Acad Sci USA. 2002;99(18):11946–50.
 99. Kaya D, Gursoy-Ozdemir Y, Yemisci M, Tuncer N, Aktan S, Dalkara T. VEGF 
protects brain against focal ischemia without increasing blood–brain 
permeability when administered intracerebroventricularly. J Cereb 
Blood Flow Metab. 2005;25(9):1111–8.
 100. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA. VEGF-
induced neuroprotection, neurogenesis, and angiogenesis after focal 
cerebral ischemia. J Clin Investig. 2003;111(12):1843–51.
 101. Liu L, Fujimoto M, Kawakita F, Nakano F, Imanaka-Yoshida K, Yoshida T, 
Suzuki H. Anti-vascular endothelial growth factor treatment suppresses 
early brain injury after subarachnoid hemorrhage in mice. Mol Neuro-
biol. 2016;53(7):4529–38.
 102. Crouthamel MH, Kelly EJ, Ho RJ. Development and characteriza-
tion of transgenic mouse models for conditional gene knock-
out in the blood-brain and blood-CSF barriers. Transgenic Res. 
2012;21(1):113–30.
 103. Kubo Y, Koji T, Kashimura H, Otawara Y, Ogawa A, Ogasawara K. Adre-
nomedullin concentration in the cerebrospinal fluid is related to appe-
tite loss and delayed ischemic neurological deficits after subarachnoid 
hemorrhage. Neurol Res. 2013;35(7):713–8.
 104. Kubo Y, Ogasawara K, Kakino S, Kashimura H, Yoshida K, Ogawa A. Cer-
ebrospinal fluid adrenomedullin concentration correlates with hypona-
tremia and delayed ischemic neurological deficits after subarachnoid 
hemorrhage. Cerebrovasc Dis. 2008;25(1–2):164–9.
 105. Balusu S, Van Wonterghem E, De Rycke R, Raemdonck K, Stremersch 
S, Gevaert K, Brkic M, Demeestere D, Vanhooren V, Hendrix A, et al. 
Identification of a novel mechanism of blood-brain communication 
during peripheral inflammation via choroid plexus-derived extracellular 
vesicles. EMBO Mol Med. 2016;8(10):1162–83.
 106. Grapp M, Wrede A, Schweizer M, Huwel S, Galla HJ, Snaidero N, Simons 
M, Buckers J, Low PS, Urlaub H, et al. Choroid plexus transcytosis and 
Page 12 of 13Xiang et al. Fluids Barriers CNS  (2017) 14:8 
exosome shuttling deliver folate into brain parenchyma. Nat Commun. 
2013;4:2123.
 107. Tietje A, Maron KN, Wei Y, Feliciano DM. Cerebrospinal fluid extracellular 
vesicles undergo age dependent declines and contain known and 
novel non-coding RNAs. PLoS ONE. 2014;9(11):e113116.
 108. Fodstad H, Kok P, Algers G. Fibrinolytic activity of cerebral tissue 
after experimental subarachnoid haemorrhage: inhibitory effect of 
tranexamic acid (AMCA). Acta Neurol Scand. 1981;64(1):29–46.
 109. Masuda T, Dohrmann GJ, Kwaan HC, Erickson RK, Wollman RL. Fibrino-
lytic activity in experimental intracerebral hematoma. J Neurosurg. 
1988;68(2):274–8.
 110. Gao C, Du H, Hua Y, Keep RF, Strahle J, Xi G. Role of red blood cell lysis 
and iron in hydrocephalus after intraventricular hemorrhage. J Cereb 
Blood Flow Metab. 2014;34(6):1070–5.
 111. Strahle JM, Garton T, Bazzi AA, Kilaru H, Garton HJ, Maher CO, Muraszko 
KM, Keep RF, Xi G. Role of hemoglobin and iron in hydrocephalus after 
neonatal intraventricular hemorrhage. Neurosurgery. 2014;75(6):696–
705 (discussion 706).
 112. Mesquita SD, Ferreira AC, Sousa JC, Santos NC, Correia-Neves M, Sousa 
N, Palha JA, Marques F. Modulation of iron metabolism in aging and in 
Alzheimer’s disease: relevance of the choroid plexus. Front Cell Neuro-
sci. 2012;6:25.
 113. Rouault TA, Zhang DL, Jeong SY. Brain iron homeostasis, the choroid 
plexus, and localization of iron transport proteins. Metab Brain Dis. 
2009;24(4):673–84.
 114. Borlongan CV, Skinner SJ, Geaney M, Vasconcellos AV, Elliott RB, Emerich 
DF. CNS grafts of rat choroid plexus protect against cerebral ischemia in 
adult rats. NeuroReport. 2004;15(10):1543–7.
 115. Matsumoto N, Taguchi A, Kitayama H, Watanabe Y, Ohta M, Yoshihara 
T, Itokazu Y, Dezawa M, Suzuki Y, Sugimoto H, et al. Transplantation of 
cultured choroid plexus epithelial cells via cerebrospinal fluid shows 
prominent neuroprotective effects against acute ischemic brain injury 
in the rat. Neurosci Lett. 2010;469(3):283–8.
 116. Kanekiyo K, Nakano N, Noda T, Yamada Y, Suzuki Y, Ohta M, Yokota A, 
Fukushima M, Ide C. Transplantation of choroid plexus epithelial cells 
into contusion-injured spinal cord of rats. Restor Neurol Neurosci. 
2016;34(3):347–66.
 117. Chauhan AN, Lewis PD. A quantitative study of cell proliferation in 
ependyma and choroid plexus in the postnatal rat brain. Neuropathol 
Appl Neurobiol. 1979;5(4):303–9.
 118. Kaplan MS. Proliferation of epithelial cells in the adult primate choroid 
plexus. Anat Rec. 1980;197(4):495–502.
 119. Barkho BZ, Monuki ES. Proliferation of cultured mouse choroid plexus 
epithelial cells. PLoS ONE. 2015;10(3):e0121738.
 120. Malinovskaya NA, Komleva YK, Salmin VV, Morgun AV, Shuvaev AN, 
Panina YA, Boitsova EB, Salmina AB. Endothelial progenitor cells physiol-
ogy and metabolic plasticity in brain angiogenesis and blood–brain 
barrier modeling. Front Physiols. 2016;7:599.
 121. Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothe-
lial progenitor cells participate in cerebral neovascularization after focal 
cerebral ischemia in the adult mouse. Circ Res. 2002;90(3):284–8.
 122. Beck H, Voswinckel R, Wagner S, Ziegelhoeffer T, Heil M, Helisch A, 
Schaper W, Acker T, Hatzopoulos AK, Plate KH. Participation of bone 
marrow-derived cells in long-term repair processes after experimental 
stroke. J Cereb Blood Flow Metab. 2003;23(6):709–17.
 123. Hamisha KN, Tfilin M, Yanai J, Turgeman G. Mesenchymal stem cells can 
prevent alterations in behavior and neurogenesis induced by Ass25-35 
administration. J Mol Neurosci. 2015;55(4):1006–13.
 124. Violatto MB, Santangelo C, Capelli C, Frapolli R, Ferrari R, Sitia L, Tortarolo 
M, Talamini L, Previdi S, Moscatelli D, et al. Longitudinal tracking of 
triple labeled umbilical cord derived mesenchymal stromal cells 
in a mouse model of amyotrophic lateral sclerosis. Stem Cell Res. 
2015;15(1):243–53.
 125. Petrovic-Djergovic D, Goonewardena SN, Pinsky DJ. Inflammatory 
Disequilibrium in Stroke. Circ Res. 2016;119(1):142–58.
 126. Wang J. Preclinical and clinical research on inflammation after intracer-
ebral hemorrhage. Prog Neurobiol. 2010;92(4):463–77.
 127. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to 
translation. Nat Med. 2011;17(7):796–808.
 128. Kim JY, Park J, Chang JY, Kim SH, Lee JE. Inflammation after ischemic 
stroke: the role of leukocytes and glial cells. Exp Neurobiol. 
2016;25(5):241–51.
 129. Vexler ZS, Yenari MA. Does inflammation after stroke affect the develop-
ing brain differently than adult brain? Dev Neurosci. 2009;31(5):378–93.
 130. Schallner N, Pandit R, LeBlanc R 3rd, Thomas AJ, Ogilvy CS, Zuckerbraun 
BS, Gallo D, Otterbein LE, Hanafy KA. Microglia regulate blood clearance 
in subarachnoid hemorrhage by heme oxygenase-1. J Clin Investig. 
2015;125(7):2609–25.
 131. Zhao X, Sun G, Ting SM, Song S, Zhang J, Edwards NJ, Aronowski J. 
Cleaning up after ICH: the role of Nrf2 in modulating microglia function 
and hematoma clearance. J Neurochem. 2015;133(1):144–52.
 132. Kowarik MC, Grummel V, Wemlinger S, Buck D, Weber MS, Berthele 
A, Hemmer B. Immune cell subtyping in the cerebrospinal fluid of 
patients with neurological diseases. J Neurol. 2014;261(1):130–43.
 133. Baruch K, Ron-Harel N, Gal H, Deczkowska A, Shifrut E, Ndifon W, Mirlas-
Neisberg N, Cardon M, Vaknin I, Cahalon L, et al. CNS-specific immunity 
at the choroid plexus shifts toward destructive Th2 inflammation in 
brain aging. Proc Natl Acad Sci USA. 2013;110(6):2264–9.
 134. Ritzel RM, Crapser J, Patel AR, Verma R, Grenier JM, Chauhan A, Jellison 
ER, McCullough LD. Age-associated resident memory CD8 T cells in the 
central nervous system are primed to potentiate inflammation after 
ischemic brain injury. J Immunol. 2016;196(8):3318–30.
 135. Yang D, Sun YY, Bhaumik SK, Li Y, Baumann JM, Lin X, Zhang Y, Lin SH, 
Dunn RS, Liu CY, et al. Blocking lymphocyte trafficking with FTY720 
prevents inflammation-sensitized hypoxic-ischemic brain injury in 
newborns. J Neurosci. 2014;34(49):16467–81.
 136. Coisne C, Engelhardt B. Tight junctions in brain barriers dur-
ing central nervous system inflammation. Antioxid Redox Signal. 
2011;15(5):1285–303.
 137. Shrestha B, Paul D, Pachter JS. Alterations in tight junction protein 
and IgG permeability accompany leukocyte extravasation across the 
choroid plexus during neuroinflammation. J Neuropathol Exp Neurol. 
2014;73(11):1047–61.
 138. Szmydynger-Chodobska J, Strazielle N, Gandy JR, Keefe TH, Zink BJ, 
Ghersi-Egea JF, Chodobski A. Posttraumatic invasion of monocytes 
across the blood-cerebrospinal fluid barrier. J Cereb Blood Flow Metab. 
2012;32(1):93–104.
 139. Szmydynger-Chodobska J, Strazielle N, Zink BJ, Ghersi-Egea JF, Cho-
dobski A. The role of the choroid plexus in neutrophil invasion after 
traumatic brain injury. J Cereb Blood Flow Metab. 2009;29(9):1503–16.
 140. Karimy JK, Duran D, Hu JK, Gavankar C, Gaillard JR, Bayri Y, Rice H, 
DiLuna ML, Gerzanich V, Marc Simard J, et al. Cerebrospinal fluid hyper-
secretion in pediatric hydrocephalus. Neurosurg Focus. 2016;41(5):E10.
 141. Scarff JE. The treatment of nonobstructive (communicating) hydro-
cephalus by endoscopic cauterization of the choroid plexuses. J 
Neurosurg. 1970;33(1):1–18.
 142. Weil AG, Westwick H, Wang S, Alotaibi NM, Elkaim L, Ibrahim GM, Wang 
AC, Ariani RT, Crevier L, Myers B, et al. Efficacy and safety of endoscopic 
third ventriculostomy and choroid plexus cauterization for infantile 
hydrocephalus: a systematic review and meta-analysis. Child’s Nerv 
Syst. 2016;32(11):2119–31.
 143. Holloway LS Jr, Cassin S. Cerebrospinal fluid dynamics in the newborn 
dog during normoxia and hypoxia. Am J Physiol. 1972;223(3):499–502.
 144. Oshio K, Watanabe H, Song Y, Verkman AS, Manley GT. Reduced 
cerebrospinal fluid production and intracranial pressure in mice lacking 
choroid plexus water channel Aquaporin-1. FASEB J. 2005;19(1):76–8.
 145. Sveinsdottir S, Gram M, Cinthio M, Sveinsdottir K, Morgelin M, Ley D. 
Altered expression of aquaporin 1 and 5 in the choroid plexus following 
preterm intraventricular hemorrhage. Dev Neurosci. 2014;36(6):542–51.
 146. Podvin S, Gonzalez AM, Miller MC, Dang X, Botfield H, Donahue JE, 
Kurabi A, Boissaud-Cooke M, Rossi R, Leadbeater WE, et al. Esophageal 
cancer related gene-4 is a choroid plexus-derived injury response gene: 
evidence for a biphasic response in early and late brain injury. PLoS 
ONE. 2011;6(9):e24609.
 147. Knowland D, Arac A, Sekiguchi KJ, Hsu M, Lutz SE, Perrino J, Steinberg 
GK, Barres BA, Nimmerjahn A, Agalliu D. Stepwise recruitment of 
transcellular and paracellular pathways underlies blood-brain barrier 
breakdown in stroke. Neuron. 2014;82(3):603–17.
Page 13 of 13Xiang et al. Fluids Barriers CNS  (2017) 14:8 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 148. Andras IE, Toborek M. Extracellular vesicles of the blood-brain barrier. 
Tissue Barriers. 2016;4(1):e1131804.
 149. Chiasserini D, van Weering JR, Piersma SR, Pham TV, Malekzadeh A, 
Teunissen CE, de Wit H, Jimenez CR. Proteomic analysis of cerebrospi-
nal fluid extracellular vesicles: a comprehensive dataset. J Proteom. 
2014;106:191–204.
 150. Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, Chalm-
ers RT, Webb DJ, Dear JW. Identification and proteomic profiling of 
exosomes in human cerebrospinal fluid. J Transl Med. 2012;10:5.
 151. Yagi Y, Ohkubo T, Kawaji H, Machida A, Miyata H, Goda S, Roy S, 
Hayashizaki Y, Suzuki H, Yokota T. Next-generation sequencing-based 
small RNA profiling of cerebrospinal fluid exosomes. Neurosci Lett. 
2017;636:48–57.
 152. Yang Y, Keene CD, Peskind ER, Galasko DR, Hu SC, Cudaback E, Wilson 
AM, Li G, Yu CE, Montine KS, et al. Cerebrospinal fluid particles in 
Alzheimer disease and Parkinson disease. J Neuropathol Exp Neurol. 
2015;74(7):672–87.
 153. Chen J, Venkat P, Zacharek A, Chopp M. Neurorestorative therapy for 
stroke. Front Hum Neurosci. 2014;8:382.
 154. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: under-
lying mechanisms and translation to the clinic. Lancet Neurol. 
2009;8(5):491–500.
